Study of Apabetalone for long COVID
Part of Infections, Lungs & breathing clinical trials.
This trial tests an experimental drug called Apabetalone for people with long COVID. You may be eligible if you have type 2 diabetes, take or are willing to take dapagliflozin, and have had long COVID symptoms for at least 2 months after your COVID infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have type 2 diabetes and be taking dapagliflozin (or be willing to start taking it)
- You must have had long COVID symptoms that started within 3 months of your COVID infection and lasted at least 2 months
- Your long COVID symptoms must significantly affect your daily life (score of 30 or higher on a standard questionnaire)
- You must have a negative COVID test at the start of the study
- You must agree to use effective contraception if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a drug called pembrolizumab, which helps the immune system, can reduce long-lasting nervous system symptoms from COVID-19 (often called long COVID). It is for people who have had symptoms like fatigue, brain fog, or dizziness for at least 6 months after a mild or moderate COVID infection.
This study compares the blood of people with ongoing long COVID symptoms to healthy people, to look for differences in immune signals and gut bacteria. It could help find better ways to diagnose or treat long COVID.
This trial tests whether a common diabetes drug, dapagliflozin (sold as Farxiga), can help relieve the symptoms of long COVID. If you've had symptoms for months after a COVID infection, this drug might help by improving how your body handles blood sugar and inflammation.
This study tests whether a commonly used drug (repurposed) can help improve Long COVID symptoms like fatigue, breathing problems, or brain fog. It is for adults 18 to 65 who had COVID-19 in the past 4 years and still have symptoms after 3 months.
This study tests whether antiviral drugs (Truvada and Selzentry) can help people with long COVID. You may qualify if you have had long COVID symptoms for at least 6 months, including fatigue and post-exertional malaise.
This study tests whether a lab-made antibody (sipavibart) can reduce Long COVID symptoms. It is for people who developed Long COVID after a confirmed COVID infection and still have moderate to severe fatigue and other ME/CFS-like symptoms.
Hear when a new Post-Acute COVID-19 Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.